US Stock Insider Trading | Royalty Pharma disclosed four insider transactions on March 4

K-LinePoet · 2026-03-29T17:57:18+00:00

On March 4, 2026, Royalty Pharma disclosed that executive Coyne Terrance P. conducted multiple sell transactions on March 2, involving a total of 22,500 shares and exceeding 1.04 million yuan, reflecting insider trading activity.

K-LinePoet

2026-03-29 17:57:18

Abstract generation in progress

On March 4, 2026, Royalty Pharma (RPRX) disclosed four insider trading transactions. On March 2, 2026, executive Coyne Terrance P. sold 22,500 shares.

[Recent Insider Trading]

Disclosure Date	Title	Name	Transaction Date	Buy/Sell	Quantity	Trade Price per Share/US$	Total Amount/US$
March 4, 2026	Executive	Coyne Terrance P.	March 2, 2026	Sold	1,292	46.67	$60,300
March 4, 2026	Executive	Coyne Terrance P.	March 2, 2026	Sold	583	47.01	$27,410
March 4, 2026	Executive	Coyne Terrance P.	March 2, 2026	Sold	22,500	46.67	$1,049,500
March 4, 2026	Executive	Coyne Terrance P.	March 2, 2026	Sold	10,400	47.01	$490,300
February 25, 2026	Executive	Coyne Terrance P.	February 23, 2026	Sold	34,800	45.32	$1,576,600
February 4, 2026	Executive	Coyne Terrance P.	February 3, 2026	Sold	6,195	42.84	$265,400
February 4, 2026	Executive	Coyne Terrance P.	February 3, 2026	Sold	108,800	42.84	$4,659,600
February 4, 2026	Executive	Coyne Terrance P.	February 2, 2026	Sold	108,400	42.08	$4,562,900
February 4, 2026	Executive	Coyne Terrance P.	February 4, 2026	Sold	20,200	43.29	$872,900
February 2, 2026	Executive	Urist Marshall	January 30, 2026	Sold	20,000	41.09	$821,800

[Company Profile]

Royalty Pharma plc was incorporated on February 6, 2020, under the laws of England and Wales. The company is the largest buyer of bio-pharmaceutical royalties and a major source of funding for innovation in the bio-pharmaceutical industry. Since its founding in 1996, the company has been a pioneer in the royalties market, partnering with innovators from academic institutions, research hospitals, and nonprofit organizations (from small- and mid-sized biotechnology companies to leading global pharmaceutical companies). The company collects a range of royalties, giving it the right to make payments directly based on the top-line sales of many industry-leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri, and Xtandi. The company directly or indirectly provides funding for innovation in the bio-pharmaceutical industry, when it co-funds later-stage clinical trials and product launches in collaboration with companies in exchange for future royalties, and when it obtains existing royalties from the original innovators.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes